04.14.25 -- STREAM Edition: The Costs Of Disengagement From China

Uncover how an integrated CLD approach, combined with cutting-edge technologies, can drive program success and accelerate the development of protein-based therapeutics.

With up to 500 mg drug-loading capability and a disintegration time of less than 30 seconds, AdvaTab is suitable for push-through blister packs and multiple-packing configurations.

Torsten Schaderdorf provides an in-depth exploration of current regulations related to Raw Materials Risk Assessment, highlighting the risk criteria and raw material scope outlined in the BioPhorum guidelines.

We showcase the development of high drug load nanocrystal based tablets and prove that nanocrystals can match the pharmacokinetic performance of ASDs while reducing the overall pill burden.

Led by Dr. Richard Johnson, Chief Scientific Officer, this 40-minute session covers the five key stages of the UpperNose development platform, highlighting the significance of target product selection.

Explore the advancing mass spectrometry, biophysical characterization, automated sample preparation, and high throughput analytics required to deliver medicines in a safe, compliant, and efficient manner.

Specializing in formulation development, clinical and commercial manufacturing, and advanced packaging solutions, we bring expertise across a diverse range of dosage forms.

Industry experts share actionable solutions for tackling raw material variability, temperature-controlled logistics, and post-manufacturing storage, ensuring efficient, scalable operations.

If we ever did implement (suffer through?) some rather large-scale “disengagement” between the U.S. and China in the biopharma industry realm, what costs would we incur?

Cytiva is just about that initial oligo synthesis, right? Wrong! Discover the full range of synthesis systems, along with the supportive tools and technologies across the entire oligo workflow, from start to finish.